Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2013

Catalyst, Isu Abxis to Develop Hemophilia B Candidate

  • Catalyst Biosciences has formed a strategic collaboration with South Korean biologics manufacturing and development company Isu Abxis to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing, and the completion of Phase I studies.

    Per the agreement, Isu Abxis will advance FIX-NG through preclinical and Phase I studies, and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an up-front licensing fee and milestone payments through the end of the Phase I trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.

    "Catalyst has significant experience in the development of next-generation coagulation factors including FVIIa, FIX, and FXa, while Isu has the biologics manufacturing expertise to make complex proteins from research through commercialization," said Nassim Usman, Ph.D., Catalyst's CEO, in a statement. "We believe that the collaboration with Isu Abxis will accelerate FIX-NG's development and ultimately provide improved therapy for hemophilia B patients."

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »